The Weill Cornell Medicine Multiple Sclerosis Center delivers comprehensive, individualized multiple sclerosis care from a team of leading specialists, including physicians who utilize highly innovative diagnostic and therapeutic tools, and healthcare professionals who address the emotional, cognitive and rehabilitative needs of patients and their families. Our center's primary clinical and investigative objectives are the stoppage and reversal of multiple sclerosis progression. Combining highly personalized clinical care excellence with an extensive regenerative research program, we pledge our commitment to provide exceptional care for individuals suffering from MS.
The MS Center is located in Manhattan at the NewYork-Presbyterian/Weill Cornell Medical Center, an internationally acclaimed academic hospital consistently ranked in the top ten hospitals in the U.S. Our MS specialists provide individualized patient care and personalized medicine, and orchestrate the contributions of a team of world-renowned neurology, neuro-ophthalmology, rehabilitative medicine, urology, neuropsychology, neuroradiology and neurosurgery clinicians, along with clinical social workers and nursing specialists.
Clinical, translational and basic research programs at the MS Center prioritize limiting disability and restoring function in MS patients. Our collaborative neuroscience, immunology and human genetic research is geared to identify novel therapeutic MS targets. Our molecular and magnetic resonance imaging programs also contribute to the development of new methods to visualize MS axons and myelin. Additionally, a massive, concerted MS Center research effort focuses on identifying drugs that promote the regeneration of myelin in MS patients. Patients at the MS Center have many opportunities to participate in a large number of ongoing clinical trials examining the effectiveness of drugs in limiting disease progression and restoring physiologic function in MS patients. Our superlative research enterprise is funded through competitive grants from the National Institutes of Health and National Multiple Sclerosis Society, biotechnology and pharmaceutical industries, and generous philanthropy.